{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:51:59Z","timestamp":1781585519669,"version":"3.54.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Hypertriglyceridemia is a frequently seen lipid disorder. It is linked to a higher risk of cardiovascular diseases and adds a significant burden on healthcare systems. Olezarsen, a novel antisense therapy targeting apolipoprotein C-III, offers effective triglyceride reduction with the convenience of infrequent dosing. This meta-analysis evaluates the safety and efficacy of olezarsen in hypertriglyceridemia to guide clinical decision-making. A comprehensive literature search across major databases identified randomized control trials comparing olezarsen with usual care in patients with hypertriglyceridemia. Data extraction and bias assessment were conducted independently, using RoB 2.0 and the GRADE framework. A meta-analysis was performed using RevMan 5.4.1, applying random effects models and assessing heterogeneity with the\n                    <jats:italic toggle=\"yes\">I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    statistic. Eight randomized controlled trials were included. Olezarsen significantly reduced triglycerides (MD \u221258.57, 95% CI \u221263.10 to \u221254.04;\n                    <jats:italic toggle=\"yes\">I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    = 13%) and apolipoprotein C-III (MD \u221269.81, 95% CI \u221275.77 to \u221263.84;\n                    <jats:italic toggle=\"yes\">I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    = 56%). Significant improvements were also observed in apolipoprotein B, nonhigh-density lipoprotein cholesterol, and achievement of TAG targets (&lt;150\u2009mg\/dL). There was no increase in overall or serious adverse events, although injection-site reactions, liver enzyme elevations, and treatment discontinuation were higher with olezarsen. Olezarsen significantly improves TAG levels and atherogenic lipid parameters in patients with hypertriglyceridemia, demonstrating robust efficacy across multiple outcomes. It maintains an overall favorable safety profile, supporting its role as a promising therapeutic option, although monitoring for liver enzymes and injection-site reactions is warranted.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000001341","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:00:48Z","timestamp":1781582448000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Olezarsen for Hypertriglyceridemia: A New Therapy Update with Systematic Review and Meta-Analysis"],"prefix":"10.1097","author":[{"given":"Nosheen","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hareem","family":"Shahid","sequence":"additional","affiliation":[{"name":"Department of Medicine, United Medical Dental College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Hamza Ahmad","family":"Choudhry","sequence":"additional","affiliation":[{"name":"Department of Medicine, Islamic International Medical College, Islamabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika","family":"Irshad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Islamic International Medical College, Islamabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira Altaf","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, United Medical Dental College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Shahid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat National Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah Naz","family":"Afridi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safwan Masaud","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Mateen","sequence":"additional","affiliation":[{"name":"Department of Medicine, United Medical Dental College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassanat","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malaika","family":"Shereen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Frontier Medical College, Abbotabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeman","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ayub Medical College, Abbotabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazzah","family":"Javaid","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzaib","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ayub Medical College, Abbotabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandara","family":"Bashir","sequence":"additional","affiliation":[{"name":"Kabir Medical College, Peshawar, Pakistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Mustafa","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaryab","family":"Bacha","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khyber Medical College, Peshawar, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"R1-20260616","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s41043-025-01054-3","article-title":"Global prevalence of dyslipidemias in the general adult population: a systematic review and meta-analysis.","volume":"44","author":"Ballena-Caicedo","year":"2025","journal-title":"J Health Popul Nutr"},{"key":"R2-20260616","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.3390\/jcm11216377","article-title":"Global trends in the epidemiology and management of dyslipidemia.","volume":"11","author":"Liu","year":"2022","journal-title":"J Clin Med"},{"key":"R3-20260616","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.5114\/aoms\/216960","article-title":"2025: The year in cardiovascular disease\u2014the year of triglyceride-lowering therapies. Can we effectively reduce triglyceride-related residual cardiovascular disease and pancreatitis risk?","volume":"21","author":"Toth","year":"2025","journal-title":"Arch Med Sci"},{"key":"R4-20260616","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk.","volume":"390","author":"Bergmark","year":"2024","journal-title":"N Engl J Med"},{"key":"R5-20260616","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.1097\/MS9.0000000000003768","article-title":"Olezarsen: FDA approval and clinical impact in familial chylomicronemia syndrome (FCS).","volume":"87","author":"Khan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R6-20260616","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome.","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"R8-20260616","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"PRISMA 2020.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R9-20260616","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R10-20260616","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","article-title":"Improving GRADE evidence tables, part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments.","volume":"74","author":"Santesso","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"R12-20260616","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R14-20260616","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides, and atherogenic lipoprotein levels.","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"R15-20260616","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridemia and at high cardiovascular risk.","volume":"43","author":"Tardif","year":"2022","journal-title":"Eur Heart J"},{"key":"R16-20260616","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","article-title":"Targeting APOC3 with olezarsen in moderate hypertriglyceridemia.","volume":"393","author":"Bergmark","year":"2025","journal-title":"N Engl J Med"},{"key":"R17-20260616","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa2512761","article-title":"Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk.","volume":"394","author":"Marston","year":"2026","journal-title":"N Engl J Med"},{"key":"R18-20260616","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12944-024-02297-5","article-title":"Efficacy and safety of olezarsen in lowering apolipoprotein C-III and triglycerides in healthy Japanese Americans.","volume":"23","author":"Karwatowska-Prokopczuk","year":"2024","journal-title":"Lipids Health Dis"},{"key":"R19-20260616","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III.","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"R20-20260616","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-mediated lowering of apoC-III.","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"R21-20260616","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","article-title":"ApoC-III inhibitors and cardiovascular risk.","volume":"21","author":"Taskinen","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"R22-20260616","doi-asserted-by":"crossref","first-page":"109263","DOI":"10.1155\/2014\/109263","article-title":"Severe\/extreme hypertriglyceridemia and LDL apheresis treatment: review of the literature and original findings.","volume":"2014","author":"Diakoumakou","year":"2014","journal-title":"Cholesterol"},{"key":"R23-20260616","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B and cardiovascular risk.","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R24-20260616","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"LDL and cardiovascular disease.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R25-20260616","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA in dyslipidemias: JACC state-of-the-art review.","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R26-20260616","first-page":"e1082","article-title":"2018 AHA\/ACC cholesterol guideline.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:00:53Z","timestamp":1781582453000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001341","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}